


# Practical Transfusion Medicine

**SIXTH EDITION**



EDITED BY  
MICHAEL F. MURPHY  
DAVID J. ROBERTS  
MARK H. YAZER  
NANCY M. DUNBAR

**WILEY** Blackwell

# Table of Contents

[Cover](#)

[Title Page](#)

[Copyright Page](#)

[List of Contributors](#)

[Preface to the Sixth Edition](#)

[1 Introduction](#)

[Blood Donation Worldwide](#)

[Changing Landscape of Transfusion Risks](#)

[Immunohaematology](#)

[Clinical Use of Blood Components: Evolution Based on Evidence](#)

[Urgent Transfusion](#)

[Patients Requiring Chronic Transfusion Support](#)

[Obstetric, Neonatal and Paediatric Transfusion Medicine](#)

[Haemostasis and Transfusion](#)

[Cellular Therapies, Transplantation, Apheresis](#)

[The Future](#)

[Conclusion](#)

[References](#)

[Part I: Basic Principles of Immunohaematology](#)

[2 Essential Immunology for Transfusion Medicine](#)

[Cellular Basis of the Immune Response](#)

[B-Cell Activation and T-Cell-Dependent Antibody Formation](#)

[Humoral Immune Response](#)

[Antibody Effector Functions](#)

[Red Blood Cell Antibodies Illustrating These Principles](#)

[Antibody and Complement-Mediated Blood Cell Destruction](#)

[Clinical Aspects Related to Alloimmunisation against Blood Cell Antigens](#)

[Acknowledgement](#)

[References](#)

[Further Reading](#)

### [3 Human Blood Group Systems](#)

[The ABO System](#)

[The Rh System](#)

[Other Blood Group Systems](#)

[Biological and Clinical Significance of Blood Group Antigens](#)

[References](#)

[Further Reading](#)

### [4 Human Leukocyte Antigens](#)

[HLA Class I Genes](#)

[HLA Class II Genes](#)

[Genetic Organisation and Expression of HLA Class II Genes](#)

[Expression of HLA Molecules](#)

[Genetics](#)

[Function of HLA Molecules](#)

[HLA Nomenclature, Gene Polymorphism and Molecular HLA Typing](#)

[Formation of HLA Antibodies](#)

[HLA Antibody Detection](#)

[Crossmatching for Compatibility Evaluation](#)

[HLA and Solid Organ Transplantation](#)

[HLA and Haematopoietic Stem Cell Transplantation](#)

[HLA and Blood Transfusion](#)

[HLA and Disease Association](#)

[HLA and Pharmacogenomics](#)

[Acknowledgements](#)

[References](#)

[Further Reading](#)

## [5 Platelet and Neutrophil Antigens](#)

[Antigens on Platelets and Neutrophils](#)

[Human Platelet Antigens](#)

[Human Neutrophil Antigens](#)

[References](#)

[Further Reading](#)

## [6 Pretransfusion Testing and the Selection of Red Cell Products for Transfusion](#)

[Determining the Recipient's ABO Group and Screening for Unexpected Antibodies](#)

[Crossmatching Techniques](#)

[Selection of Red Cells for Transfusion](#)

[Selection of Platelets and Plasma Components](#)

[References](#)

[Further Reading](#)

## [Part II: Complications of Transfusions](#)

### [7 Investigation of Acute Transfusion Reactions](#)

[Understanding the Clinical Presentation and Differential Diagnosis](#)

[General Approach for Investigation and Treatment of Acute Transfusion Reactions](#)

[Algorithm](#)

[References](#)

[Further Reading](#)

## [8 Haemolytic Transfusion Reactions](#)

[Definition of a Haemolytic Transfusion Reaction](#)

[Pathophysiology of Haemolytic Transfusion Reactions](#)

[Acute Haemolytic Transfusion Reactions](#)

[Delayed Haemolytic Transfusion Reactions](#)

[Acute Haemolysis from ABO-Incompatible Platelet Transfusions](#)

[References](#)

[Further Reading](#)

## [9 Febrile and Allergic Transfusion Reactions](#)

[Febrile Non-haemolytic Transfusion Reactions](#)

[Allergic Transfusion Reactions](#)

[References](#)

[Further Reading](#)

## [10 Transfusion-Associated Circulatory Overload](#)

[Definition](#)

[Incidence and Outcomes](#)

[Clinical Manifestations](#)

[Pathophysiology](#)

[Risk Factors](#)

[Differential Diagnosis and Evaluation](#)

[Treatment and Prevention](#)

[References](#)

## [Further Reading](#)

### [11 Transfusion-Related Acute Lung Injury \(TRALI\)](#)

#### [Definition](#)

#### [Incidence, Outcomes and Recipient Risk Factors](#)

#### [Clinical Manifestations](#)

#### [Differential Diagnosis](#)

#### [Pathogenesis](#)

#### [Mitigation Strategies](#)

#### [Patient Management](#)

#### [Reporting](#)

#### [References](#)

#### [Further Reading](#)

### [12 Purported Adverse Effects of 'Old Blood'](#)

#### [Randomised Controlled Trials of Red Blood Cell Storage Duration](#)

#### [Recent Randomised Controlled Trials of Red Blood Cell Storage Duration in Children](#)

#### [Recent Randomised Controlled Trials of Red Blood Cell Storage Duration in Adults](#)

#### [Systematic Reviews and Secondary Analyses of Randomised Controlled Trials of Red Blood Cell Storage Duration](#)

#### [Future Research](#)

#### [Conclusions](#)

#### [References](#)

#### [Further Reading](#)

### [13 Transfusion-Induced Immunomodulation](#)

#### [Mitigation of Immunomodulation after Red Cell Transfusion](#)

[Leucocyte-Reduced Allogeneic Red Cell Transfusions Reduce Mortality in Cardiac Surgery](#)

[Observational and Cohort Studies of Transfusion Immunomodulation Link Red Cell Transfusions to Both Beneficial and Adverse Outcomes](#)

[Duration of Red Cell Storage and Immunomodulation](#)

[Experimental Studies and Transfusion Immunomodulation](#)

[Conclusion](#)

[References](#)

[Further Reading](#)

#### [14 Transfusion-Associated Graft-versus-Host Disease and Microchimerism](#)

[Transfusion-Associated Graft-versus-Host Disease](#)

[Transfusion-Associated Microchimerism](#)

[References](#)

[Further Reading](#)

#### [15 Posttransfusion Purpura](#)

[Definition](#)

[Incidence](#)

[Clinical Features](#)

[Differential Diagnosis](#)

[Laboratory Investigations](#)

[Pathophysiology](#)

[Management](#)



[Prevention of Recurrence of Posttransfusion  
Purpura](#)

[References](#)

[Further Reading](#)

## [16 Heparin-Induced Thrombocytopenia](#)

[Pathogenesis](#)

[Epidemiology](#)

[Clinical Picture](#)

[Laboratory Testing](#)

[Treatment](#)

[Management of Isolated Heparin-Induced  
Thrombocytopenia](#)

[Vaccine-Induced Immune Thrombotic  
Thrombocytopenia](#)

[References](#)

[Further Reading](#)

## [17 Transfusion-Transmitted Infections](#)

[Transmission of Infections by Blood Transfusion](#)

[Transfusion-Transmitted Infections: Detection  
and Management](#)

[Interventions to Minimise the Impact of  
Transfusion-Transmitted Infection](#)

[Transfusion-Transmitted Infectious Agents](#)

[References](#)

[Further Reading](#)

## [18 Bacterial Contamination](#)

[Incidence of Bacterial Contamination](#)

[Blood Components Implicated in Adverse  
Transfusion Reactions](#)

[Contaminant Bacterial Species](#)



[Sources of Contamination](#)

[Investigation of Transfusion Reactions](#)

[Prevention Strategies](#)

[Bacterial Detection Methods](#)

[References](#)

[Further Reading](#)

## [19 Emerging Infections and Transfusion Safety](#)

[Emerging Infections](#)

[Approaches to the Management of Transfusion-Transmissible Emerging Infections](#)

[Assessing the Risk and Threat of Transfusion Transmissibility](#)

[Recognition of Transfusion Transmission of Emerging Infections](#)

[Interventions](#)

[Pandemic Preparedness](#)

[References](#)

[Further Reading](#)

## [Part III: Practice in Blood Centres and Hospitals](#)

### [20 Regulatory Aspects of Blood Transfusion](#)

[The Components of Blood Regulation](#)

[Application and Enforcement of Regulations](#)

[The Regulatory Bodies](#)

[Stakeholder Input into Regulatory Decision Making](#)

[The Role of Blood Transfusion Agencies and Health Professionals vis-à-vis Regulatory Agencies](#)

[References](#)

[Further Reading](#)

## 21 The Role of Hemovigilance in Transfusion Safety

Haemovigilance System Organisational Structures

Scope, Breadth and Analysis of Reporting

Standardisation of Data Elements for Data Capture

Data Management

Haemovigilance System Limitations

Lessons Learned from Haemovigilance

Call to Action and Future Directions

References

Further Reading

Note

## 22 Donors and Blood Collection

Blood Donors: Altruistic, Directed, Payback and Paid

Risks to the Blood Donor

Donor Selection and Deferral

Iron Deficiency in Blood Donors

Men Having Sex with Men and Blood Donation

Blood Collection/Donation Process

Obligations to Donors

Acknowledgement

References

Further Reading

## 23 Blood Donation Testing and the Safety of the Blood Supply

Red Cell Serological Testing

[ABO and D Grouping, and Detection of Red Cell Antibodies](#)

[Microbiological Testing of Blood Donations and Donor Follow-Up](#)

[Quality Framework and Operational Issues](#)

[Acknowledgements](#)

[References](#)

[Further Reading](#)

## [24 Production and Storage of Blood Components](#)

[Whole Blood and Its Processing to Components](#)

[Collection of Components by Apheresis](#)

[Regulations, Specifications and Quality Monitoring](#)

[Red Blood Cell Production and Storage](#)

[Platelet Production and Storage](#)

[Plasma Production and Storage](#)

[Cryoprecipitate Production and Storage](#)

[Granulocyte Production and Storage](#)

[Component Modifications](#)

[References](#)

[Further Reading](#)

## [25 Blood Transfusion in Hospitals](#)

[What Does Hospital Transfusion Practice Encompass?](#)

[Lessons for Hospital Blood Transfusion Practice from Haemovigilance Programmes](#)

[Key Features of Hospital Transfusion Governance](#)

[Hospital Transfusion Committees](#)

[Working Together to Improve the Transfusion Process](#)

[Administration of Blood and Blood Components and Management of the Transfused Patient](#)

[Technologies to Reduce Patient](#)

[Misidentification Errors in Administering Blood](#)

[Influencing Clinical Practice](#)

[Guidelines, Algorithms and Protocols](#)

[Clinical Audit and Feedback](#)

[Surveys](#)

[National Schemes](#)

[Public and Political Perceptions and Fear of Litigation](#)

[Local Investigation and Feedback Following 'Near-Misses' and Serious Adverse Events](#)

[Education and Continuing Professional Development](#)

[Centralisation of Transfusion Services](#)

[Maximum Surgical Blood Ordering Schedule](#)

[Acknowledgement](#)

[References](#)

[Further Reading](#)

[Guidelines and Other Resources](#)

## [26 Disaster Preparedness](#)

[Emergency Preparedness](#)

[Mass Casualty Events](#)

[Business Continuity](#)

[Acknowledgements](#)

[References](#)

[Further Reading](#)

## 27 Blood Transfusion in a Global Context

Safety and Supply

Testing Blood Products

Blood Donors

Use of Blood Products

Systems

Improvements

Pandemics

Conclusion: The Future of Blood Transfusion in a Global Context

References

Further Reading

## Part IV: Clinical Transfusion Practice

### 28 Inherited and Acquired Disorders of Haemostasis

Normal Haemostasis

Investigation of Abnormal Haemostasis

Inherited Haemostatic Defects

Acquired Haemostatic Defects

References

Further Reading

### 29 Point-of-Care Haemostasis Testing

Limitations of Conventional Coagulation Testing

Point-of-Care Testing Options

Viscoelastic Testing

Use of Point-of-Care Tests in Trauma

Use of Point-of-Care Tests in Surgical Bleeding

Supplemental Assays

Analysis of Platelet Function

[Conclusion](#)

[References](#)

[Further Reading](#)

### [30 Transfusion in Bleeding Patients](#)

[Volume Loss in Acute Bleeding](#)

[Platelet Counts](#)

[Assessment of Coagulation Factors](#)

[Massive Blood Loss](#)

[The Acute Coagulopathy of Trauma and  
Massive Injury](#)

[Principles of Haemostatic Resuscitation](#)

[The Limits of Conventional Blood Products](#)

[Laboratory Support](#)

[Evidence](#)

[Can the Lessons of Damage Control  
Resuscitation for Trauma Be Extended to Other  
Massive Haemorrhage Situations?](#)

[Tranexamic Acid](#)

[Conclusion](#)

[References](#)

[Further Reading](#)

### [31 Transfusion in Non-Bleeding Medical and Surgical Patients](#)

[Red Cell Transfusion](#)

[Thresholds for Red Cell Transfusion](#)

[Fresh Frozen Plasma](#)

[Platelet Transfusion](#)

[References](#)

## 32 Transfusion in Malignant Haematological Disease

Red Cell Transfusions

Patients Receiving Intensive

Myelosuppressive/Myeloablative Treatment

Red Cell Transfusions and Chronic Anaemias

Use of Recombinant Erythropoietin in  
Haematological Disease

Platelet Transfusions

Indications for Platelet Transfusions

Granulocyte Transfusions

Approaches to Complications Associated with  
Blood Transfusion in Patients with Malignant  
Haematological Disease

References

Further Reading

## 33 Transfusion in Benign Haematological Disease

Benign Red Blood Cell Disorders

Benign Platelet Disorders

Conclusion

References

Further Reading

## 34 Transfusion in Patients with Haemoglobinopathies

$\alpha$ -Thalassemia

$\beta$ -Thalassaemia

Red Blood Cell Transfusion in Thalassaemia

Sickle Cell Disease

Red Blood Cell Transfusion in Sickle Cell  
Disease



[Red Blood Cell Transfusion Requirements](#)  
[Complications of Red Blood Cell Transfusion in Haemoglobinopathies](#)

[Hyperhaemolysis Syndrome](#)

[Iron Overload](#)

[Acknowledgement](#)

[References](#)

[Further Reading](#)

### [35 Transfusing Neonates and Infants](#)

[Red Blood Cell Transfusion](#)

[Platelet Transfusion](#)

[Cellular Product Modifications for Neonates and Infants](#)

[Non-cellular Plasma Products](#)

[References](#)

### [36 Immunodeficiency and Immunoglobulin Therapy](#)

[Primary Immunodeficiency Disorders](#)

[Management of Immunodeficiency](#)

[References](#)

[Further Reading](#)

## [Part V: Patient Blood Management](#)

### [37 Development of a Patient Blood Management Programme](#)

[Step 1: Leverage Computerised Physician Order Entry Systems to Guide Evidence-Based Transfusions](#)

[Step 2: Reduce All Forms of Waste Related to Blood Transfusion Practices](#)

[Step 3: Promote Alternative Blood Transfusion Methods and Systems](#)

[Step 4: Promote Anaemia Management Strategies](#)

[Step 5: Limit Iatrogenic Blood Loss](#)

[Step 6: Provide Blood Management Education, Awareness and Auditing for Clinicians](#)

[Cost of Blood](#)

[References](#)

[Further Reading](#)

### [38 Perioperative Patient Blood Management](#)

[Anaemia and Surgery](#)

[Blood Transfusion](#)

[Patient Blood Management in Surgical Practice](#)

[Current Challenges and Future Research in Patient Blood Management](#)

[Conclusion](#)

[References](#)

[Further Reading](#)

### [39 Restrictive Transfusion Practice and How to Implement It](#)

[Level 1 Evidence Supports Restrictive Red Cell Transfusion Practices: Key Clinical Trials](#)

[Transfusion Triggers and Targets](#)

[Clinical Practice Guidelines](#)

[Strategies for Improving Blood Utilisation](#)

[Clinical Decision Support](#)

[Improving Blood Utilisation: The Stanford Experience](#)

[Future Directions](#)

[Conclusion](#)

[References](#)

## [Further Reading](#)

### [40 Using Data to Support Patient Blood Management](#)

#### [Transfusion Triggers and Targets](#)

#### [Blood Utilisation Metrics](#)

#### [Sources of Data](#)

#### [Data Extraction, Analysis and Presentation to Improve Practice](#)

#### [Clinical Outcome Data](#)

#### [Risk Adjustment](#)

#### [Crossmatch to Transfusion Ratio](#)

#### [Preoperative Anaemia Screening and Management](#)

#### [Conclusions](#)

#### [Conflicts of Interest](#)

#### [References](#)

#### [Further Reading](#)

### [Part VI: Cellular Therapy and Transplantation](#)

#### [41 Regulation and Accreditation in Cellular Therapy](#)

##### [Haematopoietic Stem Cell Transplant Activity](#)

##### [The Structure of Stem Cell Transplant Programmes](#)

##### [European Union Directives and Legislation](#)

##### [International Identifiers: The Single European Code](#)

##### [The Human Tissue Act 2004](#)

##### [International Identifiers: GRID Numbers](#)

##### [US Food and Drug Administration](#)

##### [Non-governmental \(Voluntary\) Accreditation](#)

[Advanced Therapy Medicinal Products](#)

[Conclusion: How Do Haematopoietic Stem Cell Transplantation Programmes Respond to the Challenge?](#)

[References](#)

[Further Reading](#)

## [42 Stem Cell Collection and Therapeutic Apheresis](#)

[Cell Separators](#)

[Patient Assessment and Treatment Planning](#)

[Haematopoietic Progenitor Cell Mobilisation](#)

[Poor Mobilisation: The Use of Plerixafor](#)

[Peripheral Blood Haematopoietic Progenitor Cell Collection \(Leucocytapheresis\)](#)

[Plasma Exchange](#)

[Red Cell Exchange](#)

[Extracorporeal Photochemotherapy](#)

[Apheresis Applications for COVID-19 Patients](#)

[Complications of Therapeutic Apheresis](#)

[References](#)

[Further Reading](#)

## [43 Haemopoietic Stem Cell Processing and Storage](#)

[Background](#)

[Transplant Procedures](#)

[Haemopoietic Progenitor Cell Products](#)

[Storage of Haemopoietic Progenitor Cell Products](#)

[Quality Assurance](#)

[References](#)

[Further Reading](#)

#### 44 Haematopoietic Cell Transplantation

Principles of Haematopoietic Cell Transplants

Indications for Haematopoietic Cell Transplants

Source of Haematopoietic Cells

Donor Care and Selection

Collecting Haematopoietic Cells

Complications of Transplantation

Late Effects

Bone Marrow Transplant Outcome

Post-Bone Marrow Transplant Chimerism and  
Molecular Monitoring

Regulatory Aspects of Haematopoietic Cell  
Transplantation

Conclusion and Future Perspectives

References

Further Reading

#### 45 CAR-T Cells and Recent Advances in Clinical Cellular Immunotherapy

Cellular Immunotherapy in Haemopoietic  
Progenitor Cell Transplantation

Non-specific T-Cell Immunotherapy

The Immune Landscape of Cancer

Tumour Antigens

Targeting Tumour Antigens with  
Immunotherapy

Chimeric Antigen Receptor T Cells

Bispecific T-Cell Engagers and Bispecific  
Antibodies

Tumour-Restricted Natural Killer Cell  
Immunotherapy

[Passive Cellular Immunotherapy of Infectious Disease](#)

[Why Do T-Cell Immunotherapies Fail?](#)

[Technical Advances Facilitating Translational Research in Cellular Immunotherapy](#)

[Future Directions](#)

[References](#)

[Further Reading](#)

#### [46 Tissue Banking](#)

[Regulation](#)

[Consent](#)

[Donor Selection and Testing](#)

[Tissue Procurement](#)

[Reducing Bacterial Contamination](#)

[Tissue Processing](#)

[Supply and Traceability of Tissues](#)

[Clinical Applications](#)

[Serious Adverse Events and Reactions](#)

[Advances in Tissue Processing and Regenerative Medicine](#)

[Conclusion](#)

[References](#)

[Further Reading](#)

#### [Part VII: Development of the Evidence Base for Transfusion](#)

##### [47 Observational and Interventional Trials in Transfusion Medicine](#)

[Types of Clinical Studies](#)

[Observational Studies](#)

[Randomised Controlled Trials](#)

[Conclusion](#)

[Acknowledgements](#)

[References](#)

[Further Reading](#)

#### [48 Getting the Most Out of the Evidence for Transfusion Medicine and Lessons from the COVID-19 Pandemic](#)

[What Is Meant by Evidence-Based Medicine?](#)

[Levels of Clinical Evidence](#)

[Appraisal of Primary Research Evidence for Its Validity and Usefulness](#)

[Evidence Base for Transfusion Medicine](#)

[Conclusion](#)

[References](#)

#### [49 A Primer on Biostatistics](#)

[Incidence and Prevalence](#)

[Statistics in Diagnostic Testing](#)

[Descriptive Statistics](#)

[Differentiating Types of Data and Statistical Tests to be Used](#)

[Determining Statistical Significance](#)

[Multiple Tests of Significance](#)

[Trial Hypotheses and Common Pitfalls of Interpretation](#)

[Meta-analyses and Forest Plots](#)

[Emerging Data Science Approaches: Predictive Analysis in Transfusion Medicine](#)

[Emerging Data Science Approaches: An Introduction to 'Big Data'](#)



[Conclusion](#)

[References](#)

[Further Reading](#)

## [50 A Primer on Health Economics](#)

[How Economists Think about the Blood Supply and Transfusions](#)

[Supply and Demand for Blood](#)

[Economic Evaluation in Transfusion Medicine](#)

[Conclusion](#)

[References](#)

[Further Reading](#)

## [51 Scanning the Future of Transfusion Medicine](#)

[Blood Centre Perspective](#)

[Hospital Transfusion Service and Patient Care Perspectives](#)

[The Future of Cellular Therapy](#)

[References](#)

[Index](#)

[End User License Agreement](#)

# **List of Tables**

## Chapter 2

[Table 2.1 Immunoglobulin classes and their functions.](#)

## Chapter 3

[Table 3.1 Human blood group systems.](#)

[Table 3.2 The ABO system.](#)

[Table 3.3 The Duffy system: phenotypes and genotypes.](#)

[Table 3.4 Nucleotide polymorphisms in the promoter region and in exon 2 of ...](#)

## Chapter 4

[Table 4.1 An example of a current HLA nomenclature.](#)

[Table 4.2 Number of recognised HLA antigens/alleles.](#)

[Table 4.3 Advantages and disadvantages of DNA-based techniques.](#)

[Table 4.4 HLA type and associated diseases \[18,19\].](#)

[Table 4.5 HLA type and associated pharmacological concerns \[19\].](#)

## Chapter 5

[Table 5.1 Antigen expression on peripheral blood cells.](#)

[Table 5.2 Human platelet antigens.](#)

[Table 5.3 Human neutrophil antigens.](#)

## Chapter 6

[Table 6.1 Expected ABO grouping patterns.](#)

[Table 6.2 ABO compatibilities between donor and recipient for red cell and ...](#)

[Table 6.3 Recommendations for selection of blood for patients with red cell...](#)

[Table 6.4 Summary of clinical studies on the rate of haemolysis following t...](#)

## Chapter 7

[Table 7.1 Summary of the signs/symptoms typically observed with different t...](#)

[Table 7.2 Summary of acute transfusion reactions. Source: Data from Callum ...](#)

## Chapter 8

[Table 8.1 Cytokines implicated in haemolytic transfusion reactions.](#)

[Table 8.2 Antibody specificities associated with haemolytic transfusion rea...](#)

[Table 8.3 Fatal haemolytic transfusion reactions reported to the Food and D...](#)

[Table 8.4 Immediate medical management of an acute transfusion reaction.](#)

[Table 8.5 Laboratory investigation of a suspected acute haemolytic transfus...](#)

## Chapter 10

[Table 10.1 Revised 2018 diagnostic surveillance criteria for transfusion-as...](#)

[Table 10.2 Risk factors for transfusion-associated circulatory overload \(TA...](#)

[Table 10.3 Differentiating transfusion-associated circulatory overload \(TAC...](#)

## Chapter 11

[Table 11.1 Updated transfusion-related acute lung injury \(TRALI\) definition...](#)

[Table 11.2 Conditions historically associated with transfusion-related acut...](#)

[Table 11.3 Comparison table to assist with pulmonary reaction classificatio...](#)

[Table 11.4 Classification of pulmonary oedema not fulfilling transfusion-re...](#)

[Table 11.5 Pathophysiological hits in the pathogenesis of transfusion-relat...](#)

## Chapter 12

[Table 12.1 Randomised controlled trials \(RCTs\) of red blood cell \(RBC\) stor...](#)

## Chapter 14

[Table 14.1 Potential methods for leucocyte inactivation.](#)

[Table 14.2 Comparison of irradiation guidelines, including dose and indicat...](#)

[Table 14.3 Indications for irradiated cellular blood components to prevent ...](#)

[Table 14.4 Cases of transfusion-associated graft-versus-host disease report...](#)

[Table 14.5 Frequency of homozygous HLA donors in various populations.](#)

## Chapter 16

[Table 16.1 Heparin-induced thrombocytopenia \(HIT\) issues relevant to transf...](#)

[Table 16.2 Heparin-induced thrombocytopenia \(HIT\) viewed as a clinical-path...](#)

[Table 16.3 The 4Ts pretest probability score.](#)

[Table 16.4 Platelet factor 4 \(PF4\)-dependent antigen assays \(immunoassays\)....](#)

[Table 16.5 A comparison of two classes of anticoagulant used to treat hepar...](#)

## Chapter 18

[Table 18.1 Summary of Food and Drug Administration \(FDA\) guidelines to enha...](#)

## Chapter 19

[Table 19.1 Selected emerging infections potentially or actually transmissib...](#)

## Chapter 20

[Table 20.1 Agencies involved in regulatory processes in blood transfusion....](#)

## Chapter 21

[Table 21.1 Key features of a haemovigilance system.](#)

[Table 21.2 Variations among haemovigilance systems.](#)

[Table 21.3 Benefits of standardised, uniform data and terminology.](#)

[Table 21.4 International Society for Blood Transfusion haemovigilance defin...](#)

[Table 21.5 Limitations of haemovigilance systems.](#)

## Chapter 22

[Table 22.1 Main adverse events or reactions in blood donors.](#)

[Table 22.2 Infection risks from blood donors.](#)

## Chapter 23

[Table 23.1 Screening tests on blood donations in five countries as of 2016....](#)

[Table 23.2 Distribution of donor screening for pathogens outside of Europe,...](#)

## Chapter 24

[Table 24.1 Specifications for red cell components.](#)

[Table 24.2 Specifications for platelet components \(90% of units must meet r...](#)

[Table 24.3 Specifications for plasma components.](#)

## Chapter 25

[Table 25.1 Process steps, risks managed, persons responsible and resources ...](#)

[Table 25.2 Examples of some errors and other problems in the transfusion pr...](#)

[Table 25.3 Activities of the hospital transfusion committee.](#)

[Table 25.4 Example of a Maximum Surgical Blood Order Schedule \(general surg...](#)

## Chapter 26

[Table 26.1 Definitions in emergency planning.](#)

[Table 26.2 Standard major incident phrases.](#)

[Table 26.3 Blood component planning for mass casualty events \(MCEs\).](#)

## Chapter 27

[Table 27.1 Prevalence of transfusion-transmissible infections in blood dona...](#)

## Chapter 28

[Table 28.1 Laboratory haemostasis screening tests.](#)

[Table 28.2 TEG/ROTEM parameters, selected abnormalities and treatment.](#)

[Table 28.3 Clinical manifestations and treatment of haemophilia A and B.](#)

[Table 28.4 Types and subtypes of von Willebrand disease \(vWD\).](#)

[Table 28.5 Comparative laboratory findings in types of von Willebrand disea...](#)

[Table 28.6 Main causes of disseminated intravascular coagulation.](#)

## Chapter 29

[Table 29.1 Comparison of TEG and ROTEM parameters.](#)

[Table 29.2 TEG® 5000 system assays \(Haemonetics Corp., Braintree, MA, USA\)....](#)

[Table 29.3 ROTEM® delta system assays \(Werfen, Bedford, MA, USA\).](#)

[Table 29.4 Example of TEG-based transfusion algorithm used at a level 1 pae...](#)

## Chapter 31

[Table 31.1 Sample practical transfusion strategies.](#)

## Chapter 33

[Table 33.1 Typical serological properties and disease associations in autoi...](#)

[Table 33.2 Summary of similarities and differences in clinical and laborato...](#)

[Table 33.3 Congenital disorders of platelet \(PLT\) function and their associ...](#)

[Table 33.4 Common anti-platelet \(PLT\) medications and their associated prop...](#)

## Chapter 34

[Table 34.1 Indications for transfusion in sickle cell disease.](#)



## Chapter 35

[Table 35.1 Guidelines for small-volume \(10–15 mL/kg\) red blood cell \(RBC\) t...](#)

[Table 35.2 Guidelines for platelet transfusion in neonates and infants.](#)

## Chapter 36

[Table 36.1 Classification of severe combined immunodeficiency.](#)

[Table 36.2 Patterns of infection as a guide to selection of immunological t...](#)

[Table 36.3 Use of intravenous immunoglobulin \(IvIg\) as an immunomodulatory ...](#)

[Table 36.4 Adverse effects of intravenous \(IvIg\) versus subcutaneous immuno...](#)

## Chapter 37

[Table 37.1 Strategy for developing a patient blood management programme.](#)

[Table 37.2 Sources of waste associated with blood transfusion.](#)

## Chapter 38

[Table 38.1 Intravenous iron formulations for total single-dose infusion.](#)

## Chapter 39

[Table 39.1 Seven key clinical trials of blood transfusion in adults.](#)

[Table 39.2 Clinical practice guidelines for red blood cell transfusion for ...](#)

## Chapter 40